Étiqueté : SARS-Cov-2


Describing the pattern of the COVID-19 epidemic in Vietnam

Given the rapid spread of the COVID-19 pandemic and the huge negative impacts it is causing, researching on COVID-19-related issues is very important for designing proactive and comprehensive public health interventions to fight against the pandemic. We describe the characteristics of COVID-19 patients detected in the two phases of the epidemic in Vietnam.

Photo fournie par l'hôpital Chang Gung 0

[Taiwan] Chang Gung trouve un anticorps monoclonal clé efficace à 90% contre le nouveau coronavirus

Début avril, l’équipe composée des chercheurs de l’Université et de l’hôpital Chang Gung, de l’Academia Sinica, du centre médical du ministère de la Défense et de l’Université Oxford avaient identifié 25 anticorps monoclonaux sur les patients atteints du Covid-19. Aujourd’hui, l’hôpital Chang Gung annonce avoir trouvé un anticorps monoclonal capable d’empêcher le virus du SARS-CoV-2 de pénétrer dans le corps humain avec une capacité de l’inhiber allant de 90% à 98%.

Sunney Xie (in the middle) and some members of his team. © Université de Pékin. 0

PKU-led team found effective SARS-CoV-2 neutralizing antibodies

Peking University, May 18, 2020: A joint research team led by Sunney Xie, Director of Beijing Advanced Innovation Center for Genomics (ICG) at Peking University (PKU) has successfully identified multiple highly potent neutralizing antibodies against the novel coronavirus SARS-CoV-2, the causative virus of the respiratory disease COVID-19, from convalescent plasma by high-throughput single-cell sequencing. Generated by human immune system, neutralizing antibodies can effectively prevent viruses from infecting cells. New results from animal studies showed that their neutralizing antibody provides a potential cure for COVID-19 as well as means for short-term prevention. This marks a major milestone in the fight against the pandemic.


Questions sur l’origine du coronavirus (SARS-CoV-2)

Régulièrement, la presse fait état de questionnements légitimes sur l’origine du coronavirus. Ces questionnements abreuvent les réseaux sociaux de brèves entre théories improbables et provocations délibérées.
Nous proposons ci-après une sélection d’articles répercutant ces débats qui secouent aussi les administrations gouvernementales en charge de la gestion de la pandémie, qui provoquent d’intenses débats dans le monde médical et qui crispent les diplomaties.

Fig. 3. Virions in the ultra sections of infected Vero E6 cells under electron microscope. (A, F) uninfected cells, (B, G) mock-treated SARS-CoV-2 virus infected cells, (C, D, H, I) infected cells with LH treatment, (E, J) infected cells with remdesivir treatment. White arrows indicated the spindle sharp of viral particles in infected cells with LH treatment. © Pharmacological Research / Elsevier 0

Lianhuaqingwen Exerts Anti-Viral and Anti-Inflammatory Activity Against Novel Coronavirus (SARS-CoV-2)

Lianhuaqingwen (LH) as traditional Chinese medicine (TCM) formula has been used to treat influenza and exerted broad-spectrum antiviral effects on a series of influenza viruses and immune regulatory effects Ding et al. (2017). The goal of this study is to demonstrate the antiviral activity of LH against the novel SARS-CoV-2 virus and its potential effect in regulating host immune response.

Fig. 1: Genome characterization of 2019-nCoV. © DR. 0

A Pneumonia Outbreak Associated With a New Coronavirus of Probable Bat Origin

Since the outbreak of severe acute respiratory syndrome (SARS) 18 years ago, a large number of SARS-related coronaviruses (SARSr-CoVs) have been discovered in their natural reservoir host, bats. Previous studies have shown that some bat SARSr-CoVs have the potential to infect humans. Here we report the identification and characterization of a new coronavirus (2019-nCoV), which caused an epidemic of acute respiratory syndrome in humans in Wuhan, China. The epidemic, which started on 12 December 2019, had caused 2,794 laboratory-confirmed infections including 80 deaths by 26 January 2020. Full-length genome sequences were obtained from five patients at an early stage of the outbreak. The sequences are almost identical and share 79.6% sequence identity to SARS-CoV. Furthermore, we show that 2019-nCoV is 96% identical at the whole-genome level to a bat coronavirus. Pairwise protein sequence analysis of seven conserved non-structural proteins domains show that this virus belongs to the species of SARSr-CoV. In addition, 2019-nCoV virus isolated from the bronchoalveolar lavage fluid of a critically ill patient could be neutralized by sera from several patients. Notably, we confirmed that 2019-nCoV uses the same cell entry receptor—angiotensin converting enzyme II (ACE2)—as SARS-CoV.

couverture de la revue Journal of Medical Virology. 0

Potential of large “first generation” human‐to‐human transmission of 2019‐nCoV

To investigate the genetic diversity, time origin, and evolutionary history of the 2019‐nCoV outbreak in China and Thailand, a total of 12 genome sequences of the virus with known sampling date (24 December 2019 and 13 January 2020) and geographic location (primarily Wuhan city, Hubei Province, China, but also Bangkok, Thailand) were analyzed. Phylogenetic and likelihood‐mapping analyses of these genome sequences were performed. On the basis of our results, the star‐like signal and topology of 2019‐nCoV may be indicative of potentially large “first generation” human‐to‐human virus transmission. We estimated that 2019‐nCoV likely originated in Wuhan on 9 November 2019 (95% credible interval: 25 September 2019 and 19 December 2019), and that Wuhan is the major hub for the spread of the 2019‐nCoV outbreak in China and elsewhere. Our results could be useful for designing effective prevention strategies for 2019‐nCoV in China and beyond.

Rechercher dans OpenEdition Search

Vous allez être redirigé vers OpenEdition Search